Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports.
Frontiers in oncology（2023）
摘要
https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022376804.
更多查看译文
关键词
neoadjuvant alectinib,lung adenocarcinoma,long-course
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要